

Direct Telephone Calls to:

Declaration for Patent Application

Docket Number: 1843.0120001/EKS/AJK

As a below named inventor, I hereby declare that: My residence, mailing address and citizenship are as stated below next to my name. I believe I am an original, first and joint inventor of the subject matter that is claimed and for which a patent is sought on the invention entitled Targeted MHC Class I Alpha3 Vaccine Delivery Systems, the specification of which is attached hereto unless the following box is checked: was filed on March 26, 2004 as United States Application Number or PCT International Application Number 10/809,790 ; and was amended on _____ (if applicable). I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application. I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or (f) or § 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or § 365(a) of any PCT international application, which designated at least one country other than the United States of America, listed below, and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or PCT international application having a filing date before that of the application on which priority is claimed. Prior Foreign Applications(s): Priority Claimed ☐ Yes ⊠ No (Application No.) (Country) (Day/Month/Year Filed) ⊠ No ☐ Yes (Application No.) (Country) (Day/Month/Year Filed) Send Correspondence to: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C. 1100 New York Avenue, N.W. Washington, D.C. 20005-3934

(202) 371-2600

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first Inventor:	Maurice ZAUDERER	
Signature of first Inventor:	Hourne Joulanar	Date: 5/28/2004
Residence:	Pittsford, New York	, ,
Citizenship:	US	
Mailing Address:	44 Woodland Road Pittsford, New York, 14534	
Full name of second Inventor:	Mark J. PARIS	
Signature of second Inventor:	My	Date: 5/28/04
Residence:	West Henrietta, New York	
Citizenship:	US	
Mailing Address:	94 Fitzpatrick Trail West Henrietta, New York, 14586	
Full name of third Inventor:	Ernest S. SMITH	
Signature of third Inventor:	Evest Smith	Date: 5/28/04
Residence:	Ontario, New York	,
Citizenship:	US	

265578

Mailing Address:

328 Boston Road

Ontario, New York, 14519

JUN 1 5 2004 20

POWER OF ATTORNEY FROM ASSIGNEE

Vaccinex, Inc., a corporation of New York, having a principal place of business at 1895 Mt. Hope Avenue, Rochester, New York 14620, is assignee of the entire right, title, and interest for the United States of America (as defined in 35 U.S.C. §100), by reason of an Assignment to the Assignee executed on of an invention known as Targeted MHC Class I Alpha3 Vaccine Delivery Systems (Attorney Docket No.1843.0120001/EKS/AJK), that is disclosed and claimed in a patent application of the same title by the inventors Maurice ZAUDERER, Mark J. PARIS and Ernest S. SMITH (said application filed on March 26, 2004 at the U.S. Patent and Trademark Office, having Application Number 10/809,790).

For the purpose of PAIR, the Customer Number is 26111.

The Assignee hereby appoint the U.S. attorneys associated with CUSTOMER NUMBER 28393 to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith, such attorneys currently being: Robert Greene Sterne, Esq., Registration No. 28,912; Edward J. Kessler, Esq., Registration No. 25,688; Jorge A. Goldstein, Esq., Registration No. 29,021; David K.S. Cornwell, Esq., Registration No. 31,944; Robert W. Esmond, Esq., Registration No. 32,893; Tracy-Gene G. Durkin, Esq., Registration No. 32,831; Michael A. Cimbala, Esq., Registration No. 33,851; Michael B. Ray, Esq., Registration No. 33,997; Robert E. Sokohl, Esq., Registration No. 36,013; Eric K. Steffe, Esq., Registration No. 36,688; Michael Q. Lee, Esq., Registration No. 35,239; Steven R. Ludwig, Esq., Registration No. 36,203; John M. Covert, Esq., Registration No. 38,759; Linda E. Alcorn, Esq., Registration No. 39,588; Lawrence B. Bugaisky, Esq., Registration No. 35,086; Donald J. Featherstone, Esq., Registration No. 37,575; Judith U. Kim, Esq., Registration No. 40,679; Timothy J. Shea, Jr., Esq., Registration No. 41,306; Patrick E. Garrett, Esq., Registration No. 39,987. The Assignees hereby grant said attorneys the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

Send correspondence to:

Customer Number 26111
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
U.S.A.

Direct phone calls to 202-371-2600.

FOR: Vaccinex, Inc.

SIGNATURE: Vaccinex, Inc.

BY: MANAICE ZAUSERER

TITLE: PRESIDENT & CEO

DATE: May 28, 2004

PTO/SB/96 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

1843.0120001/EKS/AJK

Applicant/Patent Owner: Maurice ZAUDERER, Mark J. PARIS, and Ernest S. SMITH		
Application No./Patent No.: 10/809,790 Filed/Issue Date: March 26, 2004		
Entitled: _Targeted MHC Class I Alpha3 Vaccine Delivery Systems		
<u>Vaccinex, Inc.</u> , a <u>Corporation</u> (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)		
states that it is: 1. ☑ the assignee of the entire right, title, and interest; or		
2. an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is ——————————————————————————————————		
A. [] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.		
OR		
B. [] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:		
From: To: To: The document was recorded in the Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.		
From: To: The document was recorded in the Patent and Trademark Office at		
Reel, Frame, or for which a copy thereof is attached.		
3. From:To:		
The document was recorded in the Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.		
[\cdot] Additional documents in the chain of title are listed on a supplemental sheet.		
[] Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (<i>i.e.</i> , the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the PTO. See MPEP 302.08]		
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.		
May 28, 2004 MAURICE LAUDERER		
Date Typed or pripted name		
(585) 271-2827 Marsh Localete		
Telephone number Signatule PRESIDENT & CEO		
Title		

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

DO NOT FORWARD TO ASSIGNMENT BRANCH NOT FOR RECORDATION

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: Maurice ZAUDERER, Mark J. PARIS and Ernest S. SMITH, the undersigned inventors hereby sell and assign to Vaccinex, Inc., a corporation formed under the laws of New York (the Assignee) his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

an bot

(a) in the invention(s) known as Targeted MHC Class I Alpha3 Vaccine Delivery Systems for which application(s) for patent in the United States of America has (have) been executed by the undersigned on 1) 5/28/04, 2) 5/28/04, and 3) 5/28/04 (also known as United States Application No. 10/809,790, filed March 26, 2004), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant Robert Greene Sterne, Esq., Registration No. 28,912; Edward J. Kessler, Esq., Registration No. 25,688; Jorge A. Goldstein, Esq., Registration No. 29,021; David K.S. Cornwell, Esq., Registration No. 31,944; Robert W. Esmond, Esq., Registration No. 32,893; Tracy-Gene G. Durkin, Esq., Registration No. 32,831; Michele A. Cimbala, Esq., Registration No. 33,851; Michael B. Ray, Esq., Registration No. 33,997; Robert E. Sokohl, Esq., Registration No. 36,013; Eric K. Steffe, Esq., Registration No. 36,688; Michael Q. Lee, Esq., Registration No. 35,239; Steven R. Ludwig, Esq., Registration No. 36,203; John M. Covert, Esq., Registration No. 38,759; Linda E. Alcorn, Esq., Registration No. 39,588; Lawrence B. Bugaisky, Esq., Registration No. 35,086; Donald J. Featherstone, Esq., Registration No. 33,876; Robert C. Millonig, Esq., Registration No. 34,395; Michael V. Messinger, Esq., Registration No. 37,575; Judith U. Kim, Esq., Registration No. 40,679; Timothy J. Shea, Jr., Esq., Registration No. 41,306; Patrick E. Garrett, Esq., Registration No. 39,987.; all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

DÓ NOT FORWARD TO ASSIGNMENT BRANCH NOT FOR RECORDATION

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: 5/28/2004 Signature of Inventor: Mark J. PARIS

Date: 5/28/04 Signature of Inventor: Expect S. SMITH

265634